inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 110.35401/2541-9897-2025-10-1-101-109inovmed-1072Research ArticleОБЗОРЫREVIEWSПротективный потенциал ингибиторов натрий-глюкозного котранспортера 2 типа в клинике внутренних болезней (часть 2)Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)https://orcid.org/0000-0002-5383-8355АвагимянА. А.AvagimyanAshot A.

Авагимян Ашот Арманович, к. м. н., преподаватель кафедры пропедевтики внутренних болезней

ул. Корюна 2а, Ереван, 0025

Ashot A. Avagimyan, Cand. Sci. (Med.), Assistant Professor at the Department of Internal Diseases Propaedeutics

Koryun 2a, Yerevan, 0025, Armenia

dr.ashotavagimyan@gmail.comhttps://orcid.org/0000-0003-2495-2957ШейбаниМ.SheibaniMohammad

Шейбани Мохаммад, PhD, ассистент кафедры фармакологии, школа медицины

Тегеран

Mohammad Sheibani, PhD, Assistant Professor at the Department of Pharmacology

Tehran

https://orcid.org/0000-0001-7140-0739ТрофименкоА. И.TrofimenkoArtem I.

Трофименко Артем Иванович, к. м. н., доцент кафедры патологической физиологии

Краснодар

Artem I. Trofimenko, Cand. Sci. (Med.), Associate Professor at the Pathological Physiology Department

Krasnodar

https://orcid.org/0000-0002-9743-0394ЛысовЕ. Е.LysovEvgenii E.

Лысов Евгений Евгеньевич, ассистент кафедры патологической физиологии

Краснодар

Evgenii E. Lysov, Assistant Professor at the Pathological Physiology Department

Krasnodar

https://orcid.org/0000-0001-6084-7025ХамидоваФ. М.KhamidovaFarida M.

Хамидова Фарида Муиновна, к. м. н., доцент, заведующая кафедрой патологической анатомии

Самарканд

Farida M. Khamidova, Dr. Sci. (Med.), Associate Professor, Head of the Pathological Anatomy Department

Samarkand

https://orcid.org/0000-0002-9642-7740АзнаурянА. З.AznauryanAnahit Z.

Азнаурян Анаит Захаровна, к. б. н., доцент кафедры гистологии

ул. Корюна 2а, Ереван, 0025

Anahit Z. Aznauryan, Cand. Sci. (Bio.), Associate Professor at the Histology Department

Koryun 2a, Yerevan, 0025, Armenia

https://orcid.org/0000-0001-7696-0639СукиасянЛ. М.SukiasyanLilit M.

Сукиасян Лилит Магаковна, к. м. н., научный сотрудник центральной исследовательской лаборатории

ул. Корюна 2а, Ереван, 0025

Lilit M. Sukiasyan, Cand. Sci. (Bio.), Researcher, Central Research Laboratory

Koryun 2a, Yerevan, 0025, Armenia

https://orcid.org/0009-0002-0486-0844СаакянК. Т.SahakyanKarmen T.

Саакян Кармен Тельмановна, д. б. н., профессор, заведующий кафедрой гистологии

ул. Корюна 2а, Ереван, 0025

Karmen T. Sahakyan, Dr. Sci. (Bio.), Professor, Head of the Histology Department

Koryun 2a, Yerevan, 0025, Armenia

https://orcid.org/0009-0006-5525-6566ГеворгянТ. Р.GevorgyanTamara R.

Геворгян Тамара Рубеновна, к. м. н., доцент кафедры педиатрической офтальмологии

ул. Корюна 2а, Ереван, 0025

Tamara R. Gevorgyan, Cand. Sci. (Med.), Associate Professor at the Ophthalmology Department

Koryun 2a, Yerevan, 0025, Armenia

https://orcid.org/0009-0006-3124-4157ТатоянМ. Р.TatoyanMarina R.

Татоян Марина Размиковна, д. б. н., профессор кафедры гистологии

ул. Корюна 2а, Ереван, 0025

Marina R. Tatoyan, Dr. Sci. (Bio.), Professor at the Histology Department

Koryun 2a, Yerevan, 0025, Armenia

https://orcid.org/0009-0005-1908-1116МкртчянГ. Л.MkrtchyanGayane L.

Мкртчян Гаяне Левановна, к. б. н., доцент кафедры гистологии

ул. Корюна 2а, Ереван, 0025

Gayane L. Mkrtchyan, Cand. Sci. (Bio.), Associate Professor at the Histology Department

Koryun 2a, Yerevan, 0025, Armenia

https://orcid.org/0009-0008-9572-6598МелтонянГ. Л.MeltonyanGoharik L.

Мелтонян Гоарик Левоновна, к. б. н., доцент кафедры гистологии

ул. Корюна 2а, Ереван, 0025

Goharik L. Meltonyan, Cand. Sci. (Bio.), Associate Professor at the Histology Department

Koryun 2a, Yerevan, 0025, Armenia

https://orcid.org/0009-0006-4944-5707ПетросянА. Р.PetrosyanAnna R.

Петросян Анна Рубеновна, преподаватель кафедры патологической анатомии и клинической морфологии

ул. Корюна 2а, Ереван, 0025

Anna R. Petrosyan, Lecturer at the Department of Pathological Anatomy and Clinical Morphology

Koryun 2a, Yerevan, 0025, Armenia

https://orcid.org/0000-0003-0532-148XМартемьяноваЛ. А.MartemyanovaLudmila A.

Мартемьянова Людмила Александровна, к. м. н., доцент, заведующая кафедрой патологической анатомии

Гомель

Ludmila A. Martemyanova, Cand. Sci. (Med.), Associate Professor, Head of the Pathological Anatomy Department

Gomel

https://orcid.org/0000-0001-6787-0893ПетросянР. Р.PetrosyanRuzanna R.

Петросян Рузанна Рубеновна, MD, PhD, MHPE, преподаватель анатомии, школа медицины им. Гилберта и Роуз-Мэри Шагури

Бейрут

Ruzanna R. Petrosyan, MD, PhD, MHPE, Assistant Professor (Anatomy), Gilbert and Rose-Marie Chagoury School of Medicine

Beirut

https://orcid.org/0000-0002-9457-8879УразоваО. И.UrazovaOlga I.

Уразова Ольга Ивановна, д. м. н., профессор, член-корреспондент РАН, заведующая кафедрой патофизиологии

Томск

Olga I. Urazova, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Pathophysiology Department

Tomsk

https://orcid.org/0000-0002-4165-804XПогосоваН. В.PogosovaNana V.

Погосова Нана Вачиковна, д. м. н., профессор, заместитель генерального директора по науке и профилактической кардиологии

Москва

Nana V. Pogosova, Dr. Sci. (Med.), Professor, Deputy General Director for Science and Preventive Cardiology

Moscow

https://orcid.org/0000-0002-8352-0540СаррафзадеганН.SarrafzadeganNizal

Саррафзадеган Низал, PhD, почетный профессор, директор Института кардиоваскулярных  исследований

Исфахан

Nizal Sarrafzadegan, PhD, Distinguished Professor, Isfahan Cardiovascular Research Centre

Isfahan

Ереванский государственный медицинский университет им. М. ГерациАрменияYerevan State Medical University after M. HeratsiArmeniaИранский университет медицинских наукИранIran University of Medical SciencesIslamic Republic of IranКубанский государственный медицинский университетРоссияKuban State Medical UniversityRussian FederationСамаркандский государственный медицинский университетУзбекистанSamarkand State Medical UniversityUzbekistanГомельский государственный медицинский университетБеларусьGomel State Medical UniversityBelarusЛивано-Американский университетЛиванLebanese American UniversityLebanonСибирский государственный медицинский университетРоссияSiberian State Medical UniversityRussian FederationНациональный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова; Российский университет дружбы народов им. П. ЛумумбыРоссияNational Medical Research Centre of Cardiology after Acad. E.I. Chazov; Patrice Lumumba Peoples’ Friendship University of RussiaRussian FederationИнститут сердечно-сосудистых исследований, Исфаханский университет медицинских наукИранCardiovascular Research Institute, Isfahan University of Medical SciencesIslamic Republic of Iran202530032025101101109Copyright © Авагимян А.А., Шейбани М., Трофименко А.И., Лысов Е.Е., Хамидова Ф.М., Азнаурян А.З., Сукиасян Л.М., Саакян К.Т., Геворгян Т.Р., Татоян М.Р., Мкртчян Г.Л., Мелтонян Г.Л., Петросян А.Р., Мартемьянова Л.А., Петросян Р.Р., Уразова О.И., Погосова Н.В., Саррафзадеган Н., 20252025Авагимян А.А., Шейбани М., Трофименко А.И., Лысов Е.Е., Хамидова Ф.М., Азнаурян А.З., Сукиасян Л.М., Саакян К.Т., Геворгян Т.Р., Татоян М.Р., Мкртчян Г.Л., Мелтонян Г.Л., Петросян А.Р., Мартемьянова Л.А., Петросян Р.Р., Уразова О.И., Погосова Н.В., Саррафзадеган Н.Avagimyan A.A., Sheibani M., Trofimenko A.I., Lysov E.E., Khamidova F.M., Aznauryan A.Z., Sukiasyan L.M., Sahakyan K.T., Gevorgyan T.R., Tatoyan M.R., Mkrtchyan G.L., Meltonyan G.L., Petrosyan A.R., Martemyanova L.A., Petrosyan R.R., Urazova O.I., Pogosova N.V., Sarrafzadegan N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/1072

Ингибиторы натрий-глюкозного котранспортера 2-го типа (SGLT2i) открывают новые горизонты в клинике внутренних болезней благодаря многообразию своих протективных эффектов. Во второй части данного обзора мы анализируем потенциал SGLT2i в области гепатологии, неврологии, офтальмологии и онкологии, рассматривая механизмы действия таких препаратов, как дапаглифлозин, эмпаглифлозин, канаглифлозин и др., а также их влияние на различные органы и системы.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now uncovering new possibilities in the field of internal medicine owing to their diverse protective effects. In the second part of the literature review, we explore potential applications of SGLT2i in hepatology, neurology, ophthalmology, and oncology, mechanisms of action of such drugs as dapagliflozin, empagliflozin, canagliflozin, etc, and their effect on different organs and systems.

SGLT2iгепатопротекциянейропротекцияретинопротекцияонкопротекциядапаглифлозинэмпаглифлозинканаглифлозинhepatoprotectionneuroprotectionretinoprotectiononcoprotectiondapagliflozinempagliflozincanagliflozinReferencesVafa RG, Sabahizadeh A, Mofarrah R. Guarding the heart: how SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity: SGLT-2 inhibitors and chemotherapy-induced cardiotoxicity. Curr Probl Cardiol. 2024;49(3):102350. PMID: 38128634. https://doi.org/10.1016/j.cpcardiol.2023.102350Vafa RG, Sabahizadeh A, Mofarrah R. Guarding the heart: how SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity: SGLT-2 inhibitors and chemotherapy-induced cardiotoxicity. Curr Probl Cardiol. 2024;49(3):102350. PMID: 38128634. https://doi.org/10.1016/j.cpcardiol.2023.102350Lin L, Zhong S, Zhou Y, et al. Dapagliflozin improves the dysfunction of human umbilical vein endothelial cells (HUVECs) by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2. J Diabetes Complications. 2025;39(1):108907. PMID: 39580877. https://doi.org/10.1016/j.jdiacomp.2024.108907Lin L, Zhong S, Zhou Y, et al. Dapagliflozin improves the dysfunction of human umbilical vein endothelial cells (HUVECs) by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2. J Diabetes Complications. 2025;39(1):108907. PMID: 39580877. https://doi.org/10.1016/j.jdiacomp.2024.108907AvagimyanAA, Sheibani M, Trofimenko AI, et al. Protective potential of sodium-glucose cotransporter 2 inhibitors in internal medicine (part 1). Innovative Medicine of Kuban. 2024;9(4):126– 135. https://doi.org/10.35401/2541-9897-2024-9-4-126-135AvagimyanAA, Sheibani M, TrofimenkoAI, et al. Protective potential of sodium-glucose cotransporter 2 inhibitors in internal medicine (part 1). Innovative Medicine of Kuban. 2024;9(4):126– 135. https://doi.org/10.35401/2541-9897-2024-9-4-126-135Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors- safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024;49(9):102664. https://doi.org/10.1016/j.cpcardiol.2024.102664Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors- safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024;49(9):102664. https://doi.org/10.1016/j.cpcardiol.2024.102664Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. PMID: 35287643. PMCID: PMC8919523. https://doi.org/10.1186/s12902-022-00980-1Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. PMID: 35287643. PMCID: PMC8919523. https://doi.org/10.1186/s12902-022-00980-1Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules. 2022;12(6):824. PMID: 35740949. PMCID: PMC9221336. https://doi.org/10.3390/biom12060824Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules. 2022;12(6):824. PMID: 35740949. PMCID: PMC9221336. https://doi.org/10.3390/biom12060824Nakano D, Akiba J, Tsutsumi T, et al. Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease. Med Mol Morphol. 2022;55(4):304–315. PMID: 36131166. PMCID: PMC9606064. https://doi.org/10.1007/s00795-022-00334-9Nakano D, Akiba J, Tsutsumi T, et al. Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease. Med Mol Morphol. 2022;55(4):304–315. PMID: 36131166. PMCID: PMC9606064. https://doi.org/10.1007/s00795-022-00334-9Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):812– 821. PMID: 30447037. https://doi.org/10.1111/dom.13584Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):812– 821. PMID: 30447037. https://doi.org/10.1111/dom.13584Calapkulu M, Cander S, Gul OO, Ersoy C. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. Diabetes Metab Syndr. 2019;13(2):1031–1034. PMID: 31336439. https://doi.org/10.1016/j.dsx.2019.01.016Calapkulu M, Cander S, Gul OO, Ersoy C. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. Diabetes Metab Syndr. 2019;13(2):1031–1034. PMID: 31336439. https://doi.org/10.1016/j.dsx.2019.01.016Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1(1):46–52. PMID: 29404432. PMCID: PMC5747031. https://doi.org/10.1002/hep4.1019Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1(1):46–52. PMID: 29404432. PMCID: PMC5747031. https://doi.org/10.1002/hep4.1019Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci. 2020;65(2):623–631. PMID: 30684076. https://doi.org/10.1007/s10620-019-5477-1Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci. 2020;65(2):623–631. PMID: 30684076. https://doi.org/10.1007/s10620-019-5477-1Bellanti F, Lo Buglio A, Dobrakowski M, et al. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol. 2022;28(26):3243–3257. PMID: 36051336. PMCID: PMC9331534. https://doi.org/10.3748/wjg.v28.i26.3243Bellanti F, Lo Buglio A, Dobrakowski M, et al. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol. 2022;28(26):3243–3257. PMID: 36051336. PMCID: PMC9331534. https://doi.org/10.3748/wjg.v28.i26.3243Arai T, Atsukawa M, Tsubota A, et al. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun. 2022;6(11):3073–3082. PMID: 36039537. PMCID: PMC9592771. https://doi.org/10.1002/hep4.2069Arai T, Atsukawa M, Tsubota A, et al. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun. 2022;6(11):3073–3082. PMID: 36039537. PMCID: PMC9592771. https://doi.org/10.1002/hep4.2069Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: association with improvement of fibrinolysis. J Diabetes Complications. 2020;34(11):107703. PMID: 32883567. https://doi.org/10.1016/j.jdiacomp.2020.107703Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: association with improvement of fibrinolysis. J Diabetes Complications. 2020;34(11):107703. PMID: 32883567. https://doi.org/10.1016/j.jdiacomp.2020.107703Arai T, Atsukawa M, Tsubota A, et al. Effect of sodiumglucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab. 2021;12:20420188211000243. PMID: 33815743. PMCID: PMC7989116. https://doi.org/10.1177/20420188211000243Arai T, Atsukawa M, Tsubota A, et al. Effect of sodiumglucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab. 2021;12:20420188211000243. PMID: 33815743. PMCID: PMC7989116. https://doi.org/10.1177/20420188211000243Xing B, Zhao Y, Dong B, Lv W, Zhao W. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Investig. 2020;11(5):1238– 1247. PMID: 32083798. PMCID: PMC7477503. https://doi.org/10.1111/jdi.13237Xing B, Zhao Y, Dong B, Lv W, Zhao W. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Investig. 2020;11(5):1238– 1247. PMID: 32083798. PMCID: PMC7477503. https://doi.org/10.1111/jdi.13237Simental-Mendía M, Sánchez-García A, Rodríguez-Ramírez M, Simental-Mendía LE. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021;163:105319. PMID: 33246172. https://doi.org/10.1016/j.phrs.2020.105319Simental-Mendía M, Sánchez-García A, RodríguezRamírez M, Simental-Mendía LE. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021;163:105319. PMID: 33246172. https://doi.org/10.1016/j.phrs.2020.105319Zhou P, Tan Y, Hao Z, et al. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and metaanalysis. Front Endocrinol (Lausanne). 2023;14:1144838. PMID: 36936142. PMCID: PMC10014961. https://doi.org/10.3389/fendo.2023.1144838Zhou P, Tan Y, Hao Z, et al. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and metaanalysis. Front Endocrinol (Lausanne). 2023;14:1144838. PMID: 36936142. PMCID: PMC10014961. https://doi.org/10.3389/fendo.2023.1144838Kalantari E, Zolbanin NM, Ghasemnejad-Berenji M. Protective effects of empagliflozin on methotrexate induced hepatotoxicity in rats. Biomed Pharmacother. 2024;170:115953. PMID: 38064971. https://doi.org/10.1016/j.biopha.2023.115953Kalantari E, Zolbanin NM, Ghasemnejad-Berenji M. Protective effects of empagliflozin on methotrexate induced hepatotoxicity in rats. Biomed Pharmacother. 2024;170:115953. PMID: 38064971. https://doi.org/10.1016/j.biopha.2023.115953Satyam SM, Bairy LK, Rehman A, et al. Dapagliflozin: a promising strategy to combat cisplatin-induced hepatotoxicity in Wistar rats. Biology (Basel). 2024;13(9):672. PMID: 39336099. PMCID: PMC11428795. https://doi.org/10.3390/biology13090672Satyam SM, Bairy LK, Rehman A, et al. Dapagliflozin: a promising strategy to combat cisplatin-induced hepatotoxicity in Wistar rats. Biology (Basel). 2024;13(9):672. PMID: 39336099. PMCID: PMC11428795. https://doi.org/10.3390/biology13090672Тешев А.Ф., Малышев А.В., Головин А.С. Пролиферативная диабетическая ретинопатия тяжёлых стадий: современные подходы к диагностике и лечению (систематический обзор). Российский медицинский журнал. 2024;30(1):77–85. https://doi.org/10.17816/medjrf624868.Teshev AF, Malyshev AV, Golovin AS. Proliferative diabetic retinopathy in severe stages: modern approaches to diagnosis and treatment (systematic review). Russian Medicine. 2024;30(1):77– 85. (In Russ.). https://doi.org/10.17816/medjrf624868Wong TY, Sabanayagam C. Strategies to tackle the global burden of diabetic retinopathy: from epidemiology to artificial intelligence. Ophthalmologica. 2020;243(1):9–20. PMID: 31408872. https://doi.org/10.1159/000502387Wong TY, Sabanayagam C. Strategies to tackle the global burden of diabetic retinopathy: from epidemiology to artificial intelligence. Ophthalmologica. 2020;243(1):9–20. PMID: 31408872. https://doi.org/10.1159/000502387Lahoti S, Nashawi M, Sheikh O, Massop D, Mir M, Chilton R. Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond. Cardiovasc Endocrinol Metab. 2020;10(1):3–13. PMID: 33634250. PMCID: PMC7901818. https://doi.org/10.1097/XCE.0000000000000209Lahoti S, Nashawi M, Sheikh O, Massop D, Mir M, ChiltonR. Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond. Cardiovasc Endocrinol Metab. 2020;10(1):3–13. PMID: 33634250. PMCID: PMC7901818. https://doi.org/10.1097/XCE.0000000000000209Nadelmann JB, Miller CG, McGeehan B, Yu Y, Vander-Beek BL. SGLT2 inhibitors and diabetic retinopathy progression. Graefes Arch Clin Exp Ophthalmol. 2024;262(3):753–758. PMID: 37847267. PMCID: PMC11196159. https://doi.org/10.1007/s00417-023-06273-0Nadelmann JB, Miller CG, McGeehan B, Yu Y, VanderBeek BL. SGLT2 inhibitors and diabetic retinopathy progression. Graefes Arch Clin Exp Ophthalmol. 2024;262(3):753–758. PMID: 37847267. PMCID: PMC11196159. https://doi.org/10.1007/s00417-023-06273-0Yen FS, Wei JC, Yu TS, Hung YT, Hsu CC, Hwu CM. Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes. JAMA Netw Open. 2023;6(12):e2348431. PMID: 38117497. PMCID: PMC10733799. https://doi.org/10.1001/jamanetworkopen.2023.48431Yen FS, Wei JC, Yu TS, Hung YT, Hsu CC, Hwu CM. Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes. JAMA Netw Open. 2023;6(12):e2348431. PMID: 38117497. PMCID: PMC10733799. https://doi.org/10.1001/jamanetworkopen.2023.48431Benlarbi-Ben Khedher M, Hajri K, Dellaa A, et al. Astaxanthin inhibits aldose reductase activity in Psammomys obesus, a model of type 2 diabetes and diabetic retinopathy. Food Sci Nutr. 2019;7(12):3979–3985. PMID: 31890176. PMCID: PMC6924305. https://doi.org/10.1002/fsn3.1259Benlarbi-Ben Khedher M, Hajri K, Dellaa A, et al. Astaxanthin inhibits aldose reductase activity in Psammomys obesus, a model of type 2 diabetes and diabetic retinopathy. Food Sci Nutr. 2019;7(12):3979–3985. PMID: 31890176. PMCID: PMC6924305. https://doi.org/10.1002/fsn3.1259Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. PMID: 10938048. PMCID: PMC27454. https://doi.org/10.1136/bmj.321.7258.405Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. PMID: 10938048. PMCID: PMC27454. https://doi.org/10.1136/bmj.321.7258.405American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S7–S13. PMID: 31862744. https://doi.org/10.2337/dc20-S001American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S7–S13. PMID: 31862744. https://doi.org/10.2337/dc20-S001Ott C, Jumar A, Striepe K, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1):26. PMID: 28231831. PMCID: PMC5324272. https://doi.org/10.1186/s12933-017-0510-1Ott C, Jumar A, Striepe K, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1):26. PMID: 28231831. PMCID: PMC5324272. https://doi.org/10.1186/s12933-017-0510-1Yoshizumi H, Ejima T, Nagao T, Wakisaka M. Recovery from diabetic macular edema in a diabetic patient after minimal dose of a sodium glucose co-transporter 2 inhibitor. Am J Case Rep. 2018;19:462–466. PMID: 29670074. PMCID: PMC5928754. https://doi.org/10.12659/ajcr.909708Yoshizumi H, Ejima T, Nagao T, Wakisaka M. Recovery from diabetic macular edema in a diabetic patient after minimal dose of a sodium glucose co-transporter 2 inhibitor. Am J Case Rep. 2018;19:462–466. PMID: 29670074. PMCID: PMC5928754. https://doi.org/10.12659/ajcr.909708Straznicky NE, Grima MT, Eikelis N, et al. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab. 2011;96(3):E503–E508. PMID: 21177786. https://doi.org/10.1210/jc.2010-2204Straznicky NE, Grima MT, Eikelis N, et al. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab. 2011;96(3):E503–E508. PMID: 21177786. https://doi.org/10.1210/jc.2010-2204Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015;2015:341583. PMID: 26064978. PMCID: PMC4430650. https://doi.org/10.1155/2015/341583Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015;2015:341583. PMID: 26064978. PMCID: PMC4430650. https://doi.org/10.1155/2015/341583Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35(10):2059–2068. PMID: 28598954. https://doi.org/10.1097/HJH.0000000000001434Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35(10):2059–2068. PMID: 28598954. https://doi.org/10.1097/HJH.0000000000001434Cunningham C, Jabri A, Alhuneafat L, Aneja A. A comprehensive guide to sodium glucose cotransport inhibitors. Curr Probl Cardiol. 2023;48(10):101817. PMID: 37211299. https://doi.org/10.1016/j.cpcardiol.2023.101817Cunningham C, Jabri A, Alhuneafat L, Aneja A. A comprehensive guide to sodium glucose cotransport inhibitors. Curr Probl Cardiol. 2023;48(10):101817. PMID: 37211299. https://doi.org/10.1016/j.cpcardiol.2023.101817Wang S, Xu L, Jonas JB, et al. Major eye diseases and risk factors associated with systemic hypertension in an adult Chinese population: the Beijing Eye Study. Ophthalmology. 2009;116(12):2373–2380. PMID: 19815279. https://doi.org/10.1016/j.ophtha.2009.05.041WangS, XuL, JonasJB, etal. Major eye diseases and risk factors associated with systemic hypertension in an adult Chinese population: the Beijing Eye Study. Ophthalmology. 2009;116(12):2373–2380. PMID: 19815279. https://doi.org/10.1016/j.ophtha.2009.05.041Zhang HY, Wang JY, Ying GS, Shen LP, Zhang Z. Serum lipids and other risk factors for diabetic retinopathy in Chinese type 2 diabetic patients. J Zhejiang Univ Sci B. 2013;14(5):392–399. PMID: 23645176. PMCID: PMC3650453. https://doi.org/10.1631/jzus.B1200237Zhang HY, Wang JY, Ying GS, Shen LP, Zhang Z. Serum lipids and other risk factors for diabetic retinopathy in Chinese type 2 diabetic patients. J Zhejiang Univ Sci B. 2013;14(5):392–399. PMID: 23645176. PMCID: PMC3650453. https://doi.org/10.1631/jzus.B1200237Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol. 2018;14(11):1113–1121. PMID: 30360662. https://doi.org/10.1080/17425255.2018.1541348Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol. 2018;14(11):1113–1121. PMID: 30360662. https://doi.org/10.1080/17425255.2018.1541348Li JX, Hung YT, Bair H, Hsu SB, Hsu CY, Lin CJ. Sodiumglucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study. Sci Rep. 2023;13(1):17049. PMID: 37816862. PMCID: PMC10564914. https://doi.org/10.1038/s41598-023-43893-2LiJX, HungYT, Bair H, Hsu SB, Hsu CY, Lin CJ. Sodiumglucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study. Sci Rep. 2023;13(1):17049. PMID: 37816862. PMCID: PMC10564914. https://doi.org/10.1038/s41598-023-43893-2Pascale RM, Calvisi DF, Simile MM, Feo CF, Feo F. The Warburg effect 97 years after its discovery. Cancers (Basel). 2020;12(10):2819. PMID: 33008042. PMCID: PMC7599761. https://doi.org/10.3390/cancers12102819Pascale RM, Calvisi DF, Simile MM, Feo CF, Feo F. The Warburg effect 97 years after its discovery. Cancers (Basel). 2020;12(10):2819. PMID: 33008042. PMCID: PMC7599761. https://doi.org/10.3390/cancers12102819Wang Y, Patti GJ. The Warburg effect: a signature of mitochondrial overload. Trends Cell Biol. 2023;33(12):1014– 1020. PMID: 37117116. PMCID: PMC10600323. https://doi.org/10.1016/j.tcb.2023.03.013Wang Y, Patti GJ. The Warburg effect: a signature of mitochondrial overload. Trends Cell Biol. 2023;33(12):1014– 1020. PMID: 37117116. PMCID: PMC10600323. https://doi.org/10.1016/j.tcb.2023.03.013Naeimzadeh Y, Tajbakhsh A, Nemati M, Fallahi J. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies. Eur J Pharmacol. 2024;978:176803. PMID: 38950839. https://doi.org/10.1016/j.ejphar.2024.176803Naeimzadeh Y, Tajbakhsh A, Nemati M, Fallahi J. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies. Eur J Pharmacol. 2024;978:176803. PMID: 38950839. https://doi.org/10.1016/j.ejphar.2024.176803Basak D, Gamez D, Deb S. SGLT2 inhibitors as potential anticancer agents. Biomedicines. 2023;11(7):1867. PMID: 37509506. PMCID: PMC10376602. https://doi.org/10.3390/biomedicines11071867Basak D, Gamez D, Deb S. SGLT2 inhibitors as potential anticancer agents. Biomedicines. 2023;11(7):1867. PMID: 37509506. PMCID: PMC10376602. https://doi.org/10.3390/biomedicines11071867Dhas Y, Biswas N, M R D, Jones LD, Ashili S. Repurposing metabolic regulators: antidiabetic drugs as anticancer agents. Mol Biomed. 2024;5(1):40. PMID: 39333445. PMCID: PMC11436690. https://doi.org/10.1186/s43556-024-00204-zDhas Y, Biswas N, M R D, Jones LD, Ashili S. Repurposing metabolic regulators: antidiabetic drugs as anticancer agents. Mol Biomed. 2024;5(1):40. PMID: 39333445. PMCID: PMC11436690. https://doi.org/10.1186/s43556-024-00204-zMasoudkabir F, Mohammadifard N, Mani A, et al. Shared lifestyle-related risk factors of cardiovascular disease and cancer: evidence for joint prevention. ScientificWorldJournal. 2023;2023:2404806. PMID: 37520844. PMCID: PMC10386903. https://doi.org/10.1155/2023/2404806Masoudkabir F, Mohammadifard N, Mani A, et al. Shared lifestyle-related risk factors of cardiovascular disease and cancer: evidence for joint prevention. ScientificWorldJournal. 2023;2023:2404806. PMID: 37520844. PMCID: PMC10386903. https://doi.org/10.1155/2023/2404806Phoomak C, Vaeteewoottacharn K, Silsirivanit A, et al. High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Sci Rep. 2017;7:43842. PMID: 28262738. PMCID: PMC5338328. https://doi.org/10.1038/srep43842Phoomak C, Vaeteewoottacharn K, Silsirivanit A, et al. High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Sci Rep. 2017;7:43842. PMID: 28262738. PMCID: PMC5338328. https://doi.org/10.1038/srep43842Zhou J, Zhu J, Yu SJ, et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. Biomed Pharmacother. 2020;132:110821. PMID: 33068934. https://doi.org/10.1016/j.biopha.2020.110821Zhou J, Zhu J, Yu SJ, et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. Biomed Pharmacother. 2020;132:110821. PMID: 33068934. https://doi.org/10.1016/j.biopha.2020.110821Villani LA, Smith BK, Marcinko K, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5(10):1048–1056. PMID: 27689018. PMCID: PMC5034684. https://doi.org/10.1016/j.molmet.2016.08.014Villani LA, Smith BK, Marcinko K, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5(10):1048–1056. PMID: 27689018. PMCID: PMC5034684. https://doi.org/10.1016/j.molmet.2016.08.014Kennedy SP, O’Neill M, Cunningham D, et al. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene. 2020;39(14):3028–3040. PMID: 32042115. PMCID: PMC7118022. https://doi.org/10.1038/s41388-020-1202-yKennedy SP, O’Neill M, Cunningham D, et al. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene. 2020;39(14):3028–3040. PMID: 32042115. PMCID: PMC7118022. https://doi.org/10.1038/s41388-020-1202-yNakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One. 2020;15(4):e0232283. PMID: 32343721. PMCID: PMC7188283. https://doi.org/10.1371/journal.pone.0232283Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One. 2020;15(4):e0232283. PMID: 32343721. PMCID: PMC7188283. https://doi.org/10.1371/journal.pone.0232283Yu N, Kakunda M, Pham V, et al. HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin. Mol Cell Biol. 2015;35(8):1390–1400. PMID: 25645927. PMCID: PMC4372692. https://doi.org/10.1128/MCB.01307-14Yu N, Kakunda M, Pham V, et al. HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin. Mol Cell Biol. 2015;35(8):1390–1400. PMID: 25645927. PMCID: PMC4372692. https://doi.org/10.1128/MCB.01307-14Puglisi S, Rossini A, Poli R, et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol (Lausanne). 2021;12:738848. PMID: 34745006. PMCID: PMC8567993. https://doi.org/10.3389/fendo.2021.738848Puglisi S, Rossini A, Poli R, et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol (Lausanne). 2021;12:738848. PMID: 34745006. PMCID: PMC8567993. https://doi.org/10.3389/fendo.2021.738848Cappetta D, De Angelis A, Bellocchio G, et al. Sodium-glucose cotransporter 2 inhibitors and heart failure: a bedside-to-bench journey. Front Cardiovasc Med. 2021;8:810791. PMID: 35004918. PMCID: PMC8733295. https://doi.org/10.3389/fcvm.2021.810791Cappetta D, De Angelis A, Bellocchio G, et al. Sodium-glucose cotransporter 2 inhibitors and heart failure: a bedside-to-bench journey. Front Cardiovasc Med. 2021;8:810791. PMID: 35004918. PMCID: PMC8733295. https://doi.org/10.3389/fcvm.2021.810791Liu T, Wu J, Shi S, et al. Dapagliflozin attenuates cardiac remodeling and dysfunction in rats with β-adrenergic receptor overactivation through restoring calcium handling and suppressing cardiomyocyte apoptosis. Diab Vasc Dis Res. 2023;20(4):14791641231197106. PMID: 37589258. PMCID: PMC10437211. https://doi.org/10.1177/14791641231197106Liu T, Wu J, Shi S, et al. Dapagliflozin attenuates cardiac remodeling and dysfunction in rats with β-adrenergic receptor overactivation through restoring calcium handling and suppressing cardiomyocyte apoptosis. Diab Vasc Dis Res. 2023;20(4):14791641231197106. PMID: 37589258. PMCID: PMC10437211. https://doi.org/10.1177/14791641231197106Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline associated disturbances of cardiovascular homeostasis. Curr Probl Cardiol. 2022;47(5):100909. PMID: 34167841. https://doi.org/10.1016/j.cpcardiol.2021.100909Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline associated disturbances of cardiovascular homeostasis. Curr Probl Cardiol. 2022;47(5):100909. PMID: 34167841. https://doi.org/10.1016/j.cpcardiol.2021.100909Авагимян А.А., Трофименко А.И., Шейбани М. и др. Сравнительная характеристика кардиопротекторных эффектов дапаглифлозина и триметазидина на модели доксорубицин-циклофосфамидной кардиотоксичности. Инновационная медицина Кубани. 2023;8(4):6–14. https://doi.org/10.35401/2541-9897-2023-8-4-6-14.Avagimyan AA, Trofimenko AI, Sheibani M, et al. Comparison of cardioprotective effects of dapagliflozin and trimetazidine in the model of doxorubicin-cyclophosphamide cardiotoxicity. Innovative Medicine of Kuban. 2023;8(4):6–14. (In Russ.). https://doi.org/10.35401/2541-9897-2023-8-4-6-14Avagimyan A, Kakturskiy L, Pogosova N, Ottaviani G, Rizzo M, Sarrafzadegan N. Doxorubicin and cyclophosphamide mode of chemotherapy-related cardiomyopathy: review of preclinical model. Curr Probl Cardiol. 2025;50(1):102882. PMID: 39427867. https://doi.org/10.1016/j.cpcardiol.2024.102882Avagimyan A, Kakturskiy L, Pogosova N, Ottaviani G, Rizzo M, Sarrafzadegan N. Doxorubicin and cyclophosphamide mode of chemotherapy-related cardiomyopathy: review of preclinical model. Curr Probl Cardiol. 2025;50(1):102882. PMID: 39427867. https://doi.org/10.1016/j.cpcardiol.2024.102882Avagimyan A, Pogosova N, Kakturskiy L, et al. Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury. Cardiovasc Pathol. 2024;73:107683. PMID: 39111556. https://doi.org/10.1016/j.carpath.2024.107683Avagimyan A, Pogosova N, Kakturskiy L, et al. Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury. Cardiovasc Pathol. 2024;73:107683. PMID: 39111556. https://doi.org/10.1016/j.carpath.2024.107683Avagimyan A, Sheibani M, Pogosova N, et al. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin+cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol. 2023;391:131331. PMID: 37666280. https://doi.org/10.1016/j.ijcard.2023.131331Avagimyan A, Sheibani M, Pogosova N, et al. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin+cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol. 2023;391:131331. PMID: 37666280. https://doi.org/10.1016/j.ijcard.2023.131331Симаненкова А.В., Фукс О.С., Тимкина Н.В. и др. Высокоселективный ингибитор натрий-глюкозного котранспортера 2 типа эмпаглифлозин как средство защиты головного мозга в условиях хронической недостаточности мозгового кровообращения (клинико-экспериментальное исследование). Проблемы эндокринологии. 2024;70(4):44–56. https://doi.org/10.14341/probl13336.Simanenkova AV, Fuks OS, Timkina NV, et al. Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozinas means of brain protection in conditions of chronic brain dyscirculation. Probl Endokrinol (Mosk). 2024;70(4):44–56. PMID: 39302864. PMCID: PMC11551795. (In Russ.). https://doi.org/10.14341/probl13336Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control. Int J Mol Sci. 2023;24(7):6039. PMID: 37047011. PMCID: PMC10094124. https://doi.org/10.3390/ijms24076039Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control. Int J Mol Sci. 2023;24(7):6039. PMID: 37047011. PMCID: PMC10094124. https://doi.org/10.3390/ijms24076039Mone P, Varzideh F, Jankauskas SS, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79(8):1633–1643. PMID: 35703100. PMCID: PMC9642044. https://doi.org/10.1161/HYPERTENSIONAHA.122.19586Mone P, Varzideh F, Jankauskas SS, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79(8):1633–1643. PMID: 35703100. PMCID: PMC9642044. https://doi.org/10.1161/HYPERTENSIONAHA.122.19586Zügner E, Yang HC, Kotzbeck P, et al. Differential in vitro effects of SGLT2 inhibitors on mitochondrial oxidative phosphorylation, glucose uptake and cell metabolism. Int J Mol Sci. 2022;23(14):7966. PMID: 35887308. PMCID: PMC9319636. https://doi.org/10.3390/ijms23147966Zügner E, Yang HC, Kotzbeck P, et al. Differential in vitro effects of SGLT2 inhibitors on mitochondrial oxidative phosphorylation, glucose uptake and cell metabolism. Int J Mol Sci. 2022;23(14):7966. PMID: 35887308. PMCID: PMC9319636. https://doi.org/10.3390/ijms23147966Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021;26(23):7213. PMID: 34885795. PMCID: PMC8659196. https://doi.org/10.3390/molecules26237213Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021;26(23):7213. PMID: 34885795. PMCID: PMC8659196. https://doi.org/10.3390/molecules26237213Shaikh S, Rizvi SM, Shakil S, Riyaz S, Biswas D, Jahan R. Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol Appl Biochem. 2016;63(1):145–150. PMID: 25402624. https://doi.org/10.1002/bab.1319Shaikh S, Rizvi SM, Shakil S, Riyaz S, Biswas D, Jahan R. Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol Appl Biochem. 2016;63(1):145–150. PMID: 25402624. https://doi.org/10.1002/ bab.1319Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;13:363. PMID: 31440144. PMCID: PMC6692714. https://doi.org/10.3389/fncel.2019.00363Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;13:363. PMID: 31440144. PMCID: PMC6692714. https://doi.org/10.3389/fncel.2019.00363Liu J, Shi X, Shao Y. Sodium-glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: a Mendelian randomization study. Brain Behav. 2024;14(7):e3624. PMID: 39010704. PMCID: PMC11250420. https://doi.org/10.1002/brb3.3624Liu J, Shi X, Shao Y. Sodium-glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: a Mendelian randomization study. Brain Behav. 2024;14(7):e3624. PMID: 39010704. PMCID: PMC11250420. https://doi.org/10.1002/brb3.3624Lardaro A, Quarta L, Pagnotta S, et al. Impact of sodium glucose cotransporter 2 inhibitors (SGLT2i) therapy on dementia and cognitive decline. Biomedicines. 2024;12(8):1750. PMID: 39200215. PMCID: PMC11351143. https://doi.org/10.3390/biomedicines12081750Lardaro A, Quarta L, Pagnotta S, et al. Impact of sodium glucose cotransporter 2 inhibitors (SGLT2i) therapy on dementia and cognitive decline. Biomedicines. 2024;12(8):1750. PMID: 39200215. PMCID: PMC11351143. https://doi.org/10.3390/biomedicines12081750Shourav MMI, Anisetti B, Meschia J, Lin M. Effects of sodium-glucose co-transporter 2 inhibitors on cognition in patients with diabetes: a systematic review and meta-analysis (P11-9.002). Neurology. 2024;102(17_supplement_1). https://doi.org/10.1212/wnl.0000000000205318Shourav MMI, Anisetti B, Meschia J, Lin M. Effects of sodium-glucose co-transporter 2 inhibitors on cognition in patients with diabetes: a systematic review and meta-analysis (P11-9.002). Neurology. 2024;102(17_supplement_1). https://doi.org/10.1212/wnl.0000000000205318Youn YJ, Kim S, Jeong HJ, Ah YM, Yu YM. Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis. Front Neuroendocrinol. 2024;73:101131. PMID: 38367940. https://doi.org/10.1016/j.yfrne.2024.101131.YounYJ, Kim S, Jeong HJ, AhYM, YuYM. Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis. Front Neuroendocrinol. 2024;73:101131. PMID: 38367940. https://doi.org/10.1016/j.yfrne.2024.101131.

The authors declare that there are no conflicts of interest present.